BioMedNewsBreaks

WednesdayApr 02, 2025 3:35 pm

BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $17M in Private Placement 

Polyrizon (NASDAQ: PLRZ), a biotech company specializing in innovative intranasal hydrogels, has closed its previously announced private placement of approximately $17.0 million ordinary shares and/or pre-funded and investor warrants at a price of $0.48 per ordinary unit. The company secured approximately $17.0 million in aggregate gross proceeds from the offering and intends to use the net, together with its existing cash, for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the private placement. Greenberg Traurig, P.A. acted as counsel to the company, and Kaufman & Canoles, P.C. acted as counsel to Aegis.  To…

Continue Reading

WednesdayApr 02, 2025 10:00 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net loss of $4.1 million for Q4 2024, down from $8.2 million the prior year. The company highlighted significant progress across its three oncology platforms, including the IND filing for CLD-201 targeting solid tumors and continued clinical development of CLD-101 for high-grade glioma. Preclinical data on its CLD-400 platform showed complete tumor eradication in some models. Research and development expenses fell to $1.8 million from $4.0 million year over year, while full-year net loss narrowed to $23.8 million. Calidi ended 2024 with $9.6 million in…

Continue Reading

TuesdayApr 01, 2025 1:32 pm

BioMedNewsBreaks — Fifty 1 Labs Inc. (FITY), Genetic Networks Set to Push the Boundaries of Biotechnology 

Fifty 1 Labs (OTC: FITY), a forward-thinking leader in biotechnology and health innovation, today announced a groundbreaking achievement by its recently acquired subsidiary, Genetic Networks, in space-based biotechnology. The milestone stems from over a decade of space-based functional genomics from Dr. Corey Nislow's laboratory, with the work highlighting the pivotal role of functional genomics in diverse aspects of human health and wellness. According to Dr. Nislow, the experiment findings have the potential to unlock new pathways for pharmaceutical development and human health in space exploration.  “We are thrilled to celebrate this achievement by Genetic Networks and to have Dr. Corey…

Continue Reading

TuesdayApr 01, 2025 10:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026. To view the full press release,…

Continue Reading

TuesdayApr 01, 2025 9:50 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1x1 investor meetings. A webcast of the presentation will be available via the events section of Clene’s website. To view the full press release, visit https://ibn.fm/cglcj About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving…

Continue Reading

TuesdayApr 01, 2025 9:40 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for 6,053,000 shares. Proceeds will support working capital and advance Calidi’s clinical and preclinical cancer therapy programs. To view the full press release, visit: https://ibn.fm/PnKJA About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem…

Continue Reading

FridayMar 28, 2025 11:45 am

BioMedNewsBreaks — Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research report that presented a favorable analysis, emphasizing the company's advancements in vaccine and photodynamic therapy technologies.  The study highlights promising preclinical data for CiVax(TM), a thermostabilized COVID-19 booster, which demonstrated broad immune protection in non-human primates. Zacks also notes the continued progress of HyBryte(TM), Soligenix’s lead candidate for cutaneous T-cell lymphoma (“CTCL”), now in a second confirmatory Phase 3 trial, following successful results in its first Phase 3 study. Based on its discounted cash flow model that takes into account potential future…

Continue Reading

FridayMar 28, 2025 9:46 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement 

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,325,000 shares of common stock at $0.65 per share, or pre-funded warrants in lieu of stock. Concurrently, the company will issue series G warrants to purchase up to 6,053,000 shares of common stock in a private placement. The total gross proceeds from both transactions are expected to be approximately $3.9 million before fees and expenses. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. Calidi plans to…

Continue Reading

ThursdayMar 27, 2025 12:35 pm

BioMedNewsBreaks – TransCode Therapeutics Inc. (NASDAQ: RNAZ) Secures $10M in Registered Direct Offering

TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant. The company secured approximately $10 million in gross proceeds from the offering. TransCode intends to use the proceeds primarily for product development activities, including one or more clinical trials with its lead therapeutic candidate, TTX-MC138, including related IND-enabling studies, as well as for…

Continue Reading

ThursdayMar 27, 2025 10:00 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell

Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai's Polish subsidiary submitted a €12 million non-dilutive grant application under the EU’s FENG program to fund the next development phase of PC111. The agreement positions Scinai to advance treatments for high-mortality conditions like pemphigus and Stevens-Johnson Syndrome without immunosuppression, with Pincell's leadership expected to integrate into Scinai’s expanding European operations. To view the full press release, visit https://ibn.fm/9RiEb About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company with…

Continue Reading